What is the 13F Pro Quality Score for HCM?

13F Pro ranks HUTCHMED (China) Ltd (HCM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HCM's current score at https://13fpro.ai/company/HCM (free sign-up required for the full ranking).

Where does 13F Pro source HCM data?

All HUTCHMED (China) Ltd fundamentals and ownership data come directly from SEC EDGAR. HUTCHMED (China) Ltd files with the SEC under CIK 1648257. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HCM in?

HUTCHMED (China) Ltd (HCM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HCM research updated on 13F Pro?

HCM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HUTCHMED (China) Ltd(HCM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1648257 HCM stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

51.5/100

Rank #1,521 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why HCM Scores 52/100

exact factor attribution · 2026-09-11

HCM's composite is driven by profitability and capital efficiency, held back by free cash flow and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+7.4 pts

99th pct

Capital efficiency

+4.8 pts

98th pct

Shareholder dilution

+2.1 pts

93th pct

Institutional flow

+1.1 pts

72th pct

Earnings quality

-0.6 pts

44th pct

Earnings growth

-1.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Free cash flow

-5.2 pts

15th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

HCM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for HUTCHMED (China) Ltd (HCM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HCM at 51.5/100 on a 32-signal composite quality model, placing it at rank #1,521 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), HUTCHMED (China) Ltd reports quarterly revenue of $548.5M, net income of $456.9M, an operating margin of -7.1%. Top institutional holders of HCM by reported 13-F value include SCHRODER INVESTMENT MANAGEMENT GROUP, Allianz Asset Management GmbH, STATE STREET, based on the most recent SEC filings. HCM trades on the Nasdaq exchange and files with the SEC under CIK 1648257. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HCM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HUTCHMED (China) Ltd directly from SEC EDGAR. HUTCHMED (China) Ltd's 13F Pro composite quality score has ranged between 33 and 52 since 2026, currently 51.5 — an improving long-term trajectory across 47 quarterly and live scoring snapshots.

Revenue

FY 2025

$548.5M

Net Income

FY 2025

$456.9M

Free Cash Flow

FY 2025

$-78.8M

Operating Margin

FY 2025

-7.1%

ROIC

FY 2025

-2.8%

D/E Ratio

FY 2025

0.12

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-13.0% YoY

$548.5MFY 2025

FY22 $426.4MFY23 $838.0MFY24 $630.2MFY25 $548.5M

Net Income

+1111.0% YoY

$456.9MFY 2025

FY22 $-360.8MFY23 $100.8MFY24 $37.7MFY25 $456.9M

Operating Income

+10.4% YoY

$-39.2MFY 2025

FY22 $-407.7MFY23 $18.4MFY24 $-43.7MFY25 $-39.2M

EPS (Diluted)

+1200.0% YoY

$0.52FY 2025

FY22 $-0.43FY23 $0.12FY24 $0.04FY25 $0.52

Total Assets

+37.6% YoY

$1.75BFY 2025

FY22 $1.03BFY23 $1.28BFY24 $1.27BFY25 $1.75B

Total Debt

+10.5% YoY

$143.1MFY 2025

FY22 $18.1MFY23 $141.7MFY24 $129.6MFY25 $143.1M

Op. Cash Flow

-13109.5% YoY

$-64.7MFY 2025

FY22 $-268.6MFY23 $219.3MFY24 $497.0KFY25 $-64.7M

Free Cash Flow

-352.0% YoY

$-78.8MFY 2025

FY22 $-317.6MFY23 $186.6MFY24 $-17.4MFY25 $-78.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$548.5M -13.0%	$630.2M -24.8%	$838.0M +96.5%	$426.4M +19.7%	$356.1M +56.2%	$228.0M
Net Income	$456.9M +1111.0%	$37.7M -62.6%	$100.8M +127.9%	$-360.8M -85.4%	$-194.6M -54.8%	$-125.7M
Operating Income	$-39.2M +10.4%	$-43.7M -337.9%	$18.4M +104.5%	$-407.7M -24.2%	$-328.3M -66.9%	$-196.7M
EPS (Diluted)	$0.52 +1200.0%	$0.04 -66.7%	$0.12 +127.9%	$-0.43 -72.0%	$-0.25 -38.9%	$-0.18
Total Assets	$1.75B +37.6%	$1.27B -0.4%	$1.28B +24.3%	$1.03B -25.0%	$1.37B +89.6%	$724.1M
Total Debt	$143.1M +10.5%	$129.6M -8.5%	$141.7M +682.4%	$18.1M -66.4%	$53.8M +100.3%	$26.9M
Operating Cash Flow	$-64.7M -13109.5%	$497.0K -99.8%	$219.3M +181.6%	$-268.6M -31.5%	$-204.2M -229.0%	$-62.1M
Free Cash Flow	$-78.8M -352.0%	$-17.4M -109.3%	$186.6M +158.8%	$-317.6M -35.0%	$-235.2M -236.0%	$-70.0M

Get alerted when HCM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HUTCHMED (China) Ltd including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HCM

SCHRODER INVESTMENT MANAGEMENT GROUP
$15.8M1,477,494 sh
Allianz Asset Management GmbH
$12.5M837,475 sh
STATE STREET CORP
$3.4M313,611 sh
AIA Group Ltd
$3.1M291,229 sh
M&G Plc
$2.7M242,791 sh
Amundi
$2.2M204,385 sh
JANE STREET GROUP, LLC
$2.1M194,472 sh
RENAISSANCE TECHNOLOGIES LLC
$1.4M130,200 sh
BNP PARIBAS FINANCIAL MARKETS
$1.1M104,425 sh
XY Capital Ltd
$1.1M104,130 sh

Fund	Value	Shares
SCHRODER INVESTMENT MANAGEMENT GROUP	$15.8M	1,477,494
Allianz Asset Management GmbH	$12.5M	837,475
STATE STREET CORP	$3.4M	313,611
AIA Group Ltd	$3.1M	291,229
M&G Plc	$2.7M	242,791
Amundi	$2.2M	204,385
JANE STREET GROUP, LLC	$2.1M	194,472
RENAISSANCE TECHNOLOGIES LLC	$1.4M	130,200
BNP PARIBAS FINANCIAL MARKETS	$1.1M	104,425
XY Capital Ltd	$1.1M	104,130

Companies Similar to HCM

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

RDY

DR REDDYS LABORATORIES LTD

AI score

Similar quality profile · 1 shared holders

XY Capital Ltd

TLX

Telix Pharmaceuticals Ltd

AI score

Shared smart-money ownership · 1 shared holders

XY Capital Ltd

AZN

ASTRAZENECA PLC

AI score

Similar quality profile · 1 shared holders

M&G Plc

NVO

NOVO NORDISK A S

AI score

Similar quality profile

PHG

KONINKLIJKE PHILIPS NV

AI score

Similar quality profile · 1 shared holders

XY Capital Ltd

STVN

Stevanato Group S.p.A.

AI score

Similar quality profile

SNN

SMITH & NEPHEW PLC

AI score

Similar quality profile

GSK

GSK plc

AI score

Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HCM on your watchlist

Track score changes the day HUTCHMED (China) Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HCM a good stock to buy?

13F Pro's AI-powered analysis of HUTCHMED (China) Ltd (HCM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HCM are available on the HCM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HCM is classified as a large company.

Which hedge funds own HCM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HCM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HUTCHMED (China) Ltd's investment landscape.